Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study

被引：1
|
作者：
Li, B-K. [1 ]
Yuan, Y. [1 ]
Qiao, L. [1 ]
He, W. [1 ]
Wang, G. [2 ]
Chen, H. [3 ]
Zhang, B. [4 ]
Fuxi, H. [5 ]
Qiu, J. [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] First Peoples Hosp Foshan, Dept Hepat Surg, Foshan, Peoples R China
[4] Guangzhou Panyu Dist He Xian Mem Hosp, Dept Oncol, Guangzhou, Peoples R China
[5] Panyu Cent Hosp, Canc Inst Panyu, Dept Oncol, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
949P
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [1] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    CANCER MEDICINE, 2024, 13 (09):
  • [2] Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study
    Lu, J.
    Zhu, H.
    Guo, J.
    Teng, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S671 - S671
  • [3] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Huang, Jingjun
    Guo, Yongjian
    Huang, Wensou
    Hong, Xiaotao
    Quan, Yi
    Lin, Liteng
    Zhou, Jingwen
    Liang, Licong
    Zhang, Yaqin
    Zhou, Juan
    Cai, Mingyue
    Zhu, Kangshun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 157 - 170
  • [5] Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.
    Zhang, Wei
    Zhao, Yanrong
    Ma, Guixiang
    Zhang, Yu
    Guo, Yuan
    Chen, Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC)
    Qi, Qi
    Liu, Yang
    Li, Rentao
    Liu, Yayue
    Zhang, Xihao
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [8] Regorafenib as second-line therapy in hepatocellular carcinoma
    Austin G. Duffy
    Tim F. Greten
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 141 - 142
  • [9] Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
    Parikh, Neehar D.
    Singal, Amit G.
    Hutton, David W.
    CANCER, 2017, 123 (19) : 3725 - 3731
  • [10] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
12345